logo
A03

LUBAC und seine enzymatischen Aktivitäten bei der Entwicklung und Therapie des ABC-diffusen großzelligen B-Zell-Lymphoms

It is currently unknown how the two different LUBAC-contained ubiquitin E3s, possibly differentially, affect DLBCL development and therapy and, most importantly, what the specific roles of linear ubiquitination in the pathogenesis of this disease are and how they may differ from those of the cIAPs. We plan to delineate the tumor biology of LUBAC in ABC-DLBCL (aim 1), study the impact of LUBAC’s enzymatic activities, as compared to those of cIAP1/2, on composition and functional signaling outputs of the CBM and the My-T-BCR complexes in ABC-DLBCL cells (aim 2), and determine how HOIP inhibition impacts therapies targeting other therapeutic vulnerabilities of ABC-DLBCL (aim 3).

PRINCIPAL INVESTIGATOR

Prof. Dr. rer. nat. Henning Walczak

Institut for Biochemistry

University of Cologne

Albertus-Magnus-Platz

50923 Cologne

 

CECAD - Cluster of Excellence at the University of Cologne

Joseph-Stelzmann-Straße 26

50931 Cologne

 

Dr. rer. nat. Gianmaria Liccardi

Institute of Biochemistry

University of Cologne

Albertus-Magnus-Platz

50923 Cologne